Previous 10 | Next 10 |
2024-02-14 14:07:39 ET More on Blueprint Medicines Blueprint Medicines: Looking Toppy Barron’s cites cancer and weight loss plays for biotech M&A Seeking Alpha’s Quant Rating on Blueprint Medicines Historical earnings data for Blueprint Medi...
2024-02-13 10:15:02 ET Wells Fargo analyst issues MARKET OUTPERFORM recommendation for BPMC on February 13, 2024 10:00AM ET. The previous analyst recommendation was Market Outperform. BPMC was trading at $74.52 at issue of the analyst recommendation. The overall analyst ...
2024-02-04 17:16:46 ET More on Alnylam Pharmaceuticals, Fusion Pharmaceuticals, etc. Merus Stock: Rally Seems Overdone Alnylam's Huge Opportunity Merus: (Maybe) Building A Better Bispecific Regeneron eyes Wegovy combo to improve quality of weight loss ...
Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 PR Newswire CAMBRIDGE, Mass. , Feb. 1, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live co...
2024-01-28 06:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-17 07:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-09 11:40:35 ET More on Madrigal, Viking, etc. Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play Viking: Results From 2 Clinical Trials Of Weight Loss Drug Ahead, Other Catalysts On Tap Madrigal Pharmaceuticals: Preparing For Resmetirom's Commerci...
2024-01-09 09:45:02 ET Wells Fargo analyst issues BUY recommendation for BPMC on January 9, 2024 10:00AM ET. The previous analyst recommendation was Buy. BPMC was trading at $83.615 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...
Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference PR Newswire -- AYVAKIT ® (avapritinib) launch in indolent systemic mastocytosis to drive strong revenue growth in 2024, with ongoing U.S. la...
2024-01-04 16:28:54 ET Summary Today, we take a look at Blueprint Medicines Corporation, whose shares have nearly doubled in the past two months due to strong sales of its precision medicine Ayvakit. Ayvakit's label expansion into indolent systemic mastocytosis suggests blockbuste...
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire CAMBRIDGE, Mass. , April 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and w...
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics PR Newswire -- Dr. Mariana Castells , M.D., Ph.D., a renowned researcher and clinical expert in mast cell diseases, will join members ...
2024-04-10 04:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...